National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Cancer Institute funds early phase clinical trials for cancer treatment and diagnosis, focusing on targeted interventions relevant to specific research programs.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal / Resubmission / Revision) | January 7, 2027 (Closing date)
Funding Amounts: Up to $499,999 in direct costs annually for up to 5 years
Summary: Supports investigator-initiated Phase 0, I, and II clinical trials of cancer-targeted diagnostic and therapeutic interventions.
Key Information: At least one NIH-defined clinical trial must be completed within the project period; Phase III trials are excluded.
Description
The National Cancer Institute (NCI) offers this R01 program for investigator-initiated early-phase clinical trials that improve cancer diagnosis and treatment. Projects must align with the Division of Cancer Treatment and Diagnosis (DCTD) or Office of HIV and AIDS Malignancies (OHAM). Relevant programs cover cancer therapy evaluation, imaging, diagnosis, radiation research, complementary and alternative medicine, and HIV/AIDS malignancies.
Supported work includes evaluations of anticancer drugs and biologics, immunotherapies, imaging technologies, surgical interventions, radiation approaches, biomarkers, and integrative medicine. Trials may stand alone or accompany other research aims. Single-site, multi-site, mechanistic, feasibility, pragmatic, ancillary, pharmacodynamic, biomarker-driven, co-clinical, and HIV/AIDS-related trials are supported, including randomized Phase II trials within the program’s time and budget limits. Preliminary data must support the rationale, but interventions need not themselves be innovative if they address important questions or unmet needs.
